Results 81 to 90 of about 10,540,033 (277)

Interferon Lambda: A New Sword in Cancer Immunotherapy

Clinical and Developmental Immunology, 2011
The discovery of the interferon-lambda (IFN-λ) family has considerably contributed to our understanding of the role of interferon not only in viral infections but also in cancer. IFN-λ proteins belong to the new type III IFN group.
Ahmed Lasfar, Walid Abushahba, Murugabaskar Balan, Karine A. Cohen-Solal   +3 more
doaj   +1 more source

Regulation and Function of Interferon-Lambda (IFNλ) and Its Receptor in Asthma

Frontiers in Immunology, 2021
Asthma is a chronic respiratory disease affecting people of all ages, especially children, worldwide. Origins of asthma are suggested to be placed in early life with heterogeneous clinical presentation, severity and pathophysiology.
Susanne Krammer, Cristina Sicorschi Gutu, Janina C. Grund, Mircea T. Chiriac, Sabine Zirlik, Susetta Finotto   +5 more
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Epstein-Barr Virus LF2: an Antagonist to Type 1 Interferon [PDF]

, 2009
Upon viral infection, the major defense mounted by the host immune system is activation of the interferon (IFN)-mediated antiviral pathway, which is mediated by IFN regulatory factors (IRFs).
Shin, Young Chul, Johannsen, Eric, Haas, Juergen, Hyun Joo, Chul, Fossum, Even, Hutt-Fletcher, Lindsay M., Wu, L., Inn, Kyung-Soo, Jung, Jae U.   +8 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Type III interferon enhances the direct antitumor activity of type I interferon [PDF]

, 2011
The antitumor activities of type III interferon (IFN) (interleukin (IL)-28 and IL-29) and the combination between type III IFN and type I IFN (IFN-α) were evaluated in in vitro and in vivo studies using human non-small cell lung cancer (NSCLC).
藤江, 瞳, 牛, 凱軍, 渡辺, みか, 鈴木, 貴, 沼崎, 宗夫, 田中, 利明, 中山, 勝敏, 田川, 雅敏, Toshiaki Tanaka, Masatoshi Tagawa, Katsutoshi Nakayama, Mika Watanabe, Suzuki, Takashi, Takashi Suzuki, Fujie, Hitomi, Tagawa, Masatoshi, Numasaki, Muneo, Niu Kaijun, Nakayama, Katsutoshi, Tanaka, Toshiaki, Muneo Numasaki, Kaijun, Niu, Hitomi Fujie, Watanabe, Mika   +23 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Herpes simplex virus triggers and then disarms a host antiviral response [PDF]

, 2001
Virus infection induces an antiviral response that is predominantly associated with the synthesis and secretion of soluble interferon. Here, we report that herpes simplex virus type 1 virions induce an interferon-independent antiviral state in human ...
Smiley, J R, Macgregor, P F, Edwards, A M, Mossman, K L, Rozmus, J J, Goryachev, A B   +5 more
core   +1 more source

Subtype-specific functions of basal IFNλs

Journal of Virology
Type III interferons (IFNλs) represent the newest interferon family, comprising four human subtypes (IFNλ1–4) that signal through the tissue-restricted IFNLR1 receptor. While traditionally characterized as antiviral cytokines protecting mucosal barriers,
Megan L. Stanifer
doaj   +1 more source